Lp-PLA2

Vascular-specific inflammation - more specific to arterial wall biology than hs-CRP.

What Lp-PLA2 Measures

Lp-PLA2 is an enzyme produced by macrophages and bound to LDL particles inside arterial walls. Unlike hs-CRP (general systemic inflammation), Lp-PLA2 is relatively specific to vascular inflammation and plaque instability. Elevation correlates with plaque rupture risk independent of LDL-C.

The FDA-cleared PLAC Test is the standard assay. It adds incremental risk information over the standard lipid panel, particularly in patients with unexplained CV events or strong family history.

What Affects This Biomarker

Lp-PLA2 is influenced by: active vascular inflammation, plaque burden, smoking, LDL levels (substrate availability), and statins (reduce it). Unlike hs-CRP, it is relatively unaffected by infection, arthritis, or acute inflammation - making it cleaner for cardiovascular risk assessment.

In the Context of Peptide Protocols

Order when hs-CRP is chronically elevated for non-cardiac reasons, or when refining risk stratification in family history of early events. Not commonly repeated more than annually unless tracking response to a targeted anti-inflammatory or lipid intervention.

Deep Dive

Lp-PLA2 is one of the more specialized cardiovascular risk markers in lab medicine. Unlike the LDL cholesterol number that anchors most lipid panels or hs-CRP that measures systemic inflammation broadly, Lp-PLA2 is enzyme activity specific to vascular wall biology. It tells you something the standard panel misses: whether the inflammation happening inside your arteries is active right now.

What the PLAC Test actually measures

Lp-PLA2 is short for Lipoprotein-associated Phospholipase A2. It is an enzyme produced by macrophages, lymphocytes, and mast cells. In healthy circulation, it travels bound mostly to LDL particles. The clinical relevance comes from what it does when those LDL particles enter the arterial wall.

Inside the wall, Lp-PLA2 hydrolyzes oxidized phospholipids on the surface of trapped LDL, generating lysophosphatidylcholine and oxidized free fatty acids. Both products are bioactive. They promote macrophage chemotaxis, foam cell formation, and endothelial dysfunction. In other words, elevated Lp-PLA2 in serum is a window into ongoing intraplaque inflammation, the chemistry that drives the soft, vulnerable plaques most likely to rupture and cause heart attacks or strokes.

The FDA-cleared PLAC Test by Diadexus, now part of GenMark, is the standard commercial assay. It is available through Quest, LabCorp, and most direct-to-consumer testing platforms. The reference cutoff most clinicians use is below 200 nmol/min/mL. Values above this correlate with elevated cardiovascular event risk independent of LDL cholesterol [1].

Why Lp-PLA2 is not just another inflammation marker

hs-CRP is the classic inflammation marker reported on optimization panels, and it is undeniably useful. But hs-CRP measures whole-body inflammation. It rises with infections, autoimmune flares, arthritis, gum disease, recent surgery, and dozens of other conditions unrelated to your arteries. A high hs-CRP in someone with rheumatoid arthritis tells you their RA is active. It does not tell you their cardiovascular risk has spiked.

Lp-PLA2 is different. It is vascular-selective, relatively resistant to systemic inflammation noise. A bad cold or a flare of inflammatory bowel disease will spike hs-CRP dramatically but barely move Lp-PLA2. This makes it especially useful in two clinical scenarios. First, when hs-CRP is chronically elevated for a non-cardiac reason, Lp-PLA2 can help separate "your arteries are fine, your joints are inflamed" from "your arteries are inflamed too." Second, in patients with established cardiovascular disease, Lp-PLA2 helps stratify who is at higher risk of recurrent events.

The MONICA/KORA Augsburg study [2] and the ARIC study [3] both demonstrated that elevated Lp-PLA2 mass and activity independently predict ischemic stroke and coronary events even after adjusting for traditional risk factors. The hazard ratios are not huge, typically 1.2 to 1.5 for top versus bottom quartile, but the marker adds incremental information to a panel that has not had much to add since the introduction of ApoB.

Who actually benefits from the test

Lp-PLA2 is not a routine screening marker for healthy 30-year-olds with normal lipids. It is most useful in specific contexts.

Strong family history of premature cardiovascular events, especially events that happened to family members with otherwise unremarkable lipid panels. If your father had a heart attack at 52 despite "normal cholesterol,"Lp-PLA2 may help explain residual risk and inform whether a more aggressive prevention strategy is warranted.

Patients with chronically elevated hs-CRP from a known non-cardiac source. Rheumatoid arthritis, Hashimoto's thyroiditis, inflammatory bowel disease, and chronic infections all elevate hs-CRP. Lp-PLA2 is a cleaner read on vascular inflammation in these patients.

Patients already on statins with residual risk. Statins reduce both LDL and Lp-PLA2, but the response is variable. A patient with appropriately reduced LDL who still has elevated Lp-PLA2 may have residual inflammation that warrants additional intervention, whether that is intensifying lipid-lowering, addressing lifestyle factors, or adding anti-inflammatory therapy.

Patients with diabetes or metabolic syndrome. The combined inflammatory and metabolic burden of these conditions accelerates atherosclerosis. Lp-PLA2 captures the vascular component in a way the lipid panel alone does not.

What moves Lp-PLA2

The dominant lever is statin therapy. Statins reduce Lp-PLA2 by 20 to 30 percent on average, in line with their LDL-lowering effect. Intensive statin therapy can drop it further, though the relationship is not perfectly linear with LDL change [4].

Lifestyle interventions that improve lipid profiles also tend to reduce Lp-PLA2. Mediterranean dietary patterns, regular aerobic exercise, weight loss, and smoking cessation all reduce it modestly over months. The effect sizes are smaller than statin therapy but meaningful at the population level.

Specific anti-inflammatory interventions have variable effects. Omega-3 supplementation at therapeutic doses, 2 to 4 grams of EPA plus DHA daily, reduces Lp-PLA2 modestly in some studies, though the magnitude is not as large as statin effect. Aspirin has minimal effect. Colchicine, used in the COLCOT trial for post-MI secondary prevention, reduces inflammatory markers broadly but specific Lp-PLA2 effects are less well-characterized.

Factors that raise Lp-PLA2 include smoking, advancing age, male sex, obesity especially visceral adiposity, and uncontrolled type 2 diabetes. Acute infection does not raise it the way it does hs-CRP. This is the key clinical distinction.

Protocol context for peptide and longevity users

Lp-PLA2 is not commonly checked on the standard longevity optimization panel that most peptide users run. It belongs to a more advanced cardiovascular risk panel that complements the standard lipid panel of ApoB, lipoprotein(a), and small dense LDL.

Where it becomes relevant for protocol users is when conventional risk factors do not fully explain the cardiovascular picture. A user running peptides for healing or anti-aging who has a strong family history of premature events but normal ApoB might learn from Lp-PLA2 that there is residual vascular inflammation that warrants attention, whether that is improved omega-3 intake, addressing periodontal disease, or working with a clinician on more aggressive prevention.

Peptide protocols themselves rarely move Lp-PLA2 meaningfully. BPC-157 and TB-500 reduce systemic inflammation but do not have specific vascular-wall data. GHK-Cu has theoretical anti-inflammatory effects but no Lp-PLA2 data. GLP-1 agonists improve cardiovascular outcomes through several mechanisms including weight loss and glycemic improvement, but specific Lp-PLA2 reduction has not been a primary endpoint in trials.

The practical recommendation is to use Lp-PLA2 as a one-time risk stratification tool when it adds clinical information, rather than as a tracking marker that you serially measure to gauge protocol response. Annual or every-two-years measurement is appropriate when warranted.

Common interpretation traps

The marker is more useful for identifying high-risk individuals than for tracking small individual changes. A value of 220 versus 195 nmol/min/mL is not a dramatic difference; both are in the borderline range. The most informative use is identifying patients with values clearly above 300. Those are at meaningfully elevated risk regardless of LDL.

Confusing Lp-PLA2 with Lp(a) is a common error. Lipoprotein(a), Lp(a), is a genetic lipoprotein variant. Lp-PLA2 is the enzyme. The names look similar; the biology is completely different. Both are useful but for different reasons.

Statins reduce Lp-PLA2 along with LDL, so post-statin values should be interpreted in context. A normal Lp-PLA2 on statin therapy does not have the same prognostic meaning as the same value off statin.

The PLAC Test reports activity, the enzyme function, but research studies sometimes report mass, the amount of protein. The two correlate but are not interchangeable. Stick with the same test type for serial measurements.

Lp-PLA2 in the modern cardiovascular workup

The modern cardiovascular risk workup has shifted meaningfully in the last decade. Where 2010-era cardiology relied heavily on total cholesterol, LDL-C, and HDL-C, the contemporary practice uses ApoB as the primary atherogenic-particle marker, Lp(a) as the genetic-risk marker, hs-CRP for inflammation, and coronary artery calcium scoring for direct plaque visualization. Lp-PLA2 sits inside this matrix as a vascular-inflammation-specific marker, not a replacement for the others.

The most defensible use case for Lp-PLA2 in 2026 is the "borderline statin decision" scenario. A 50-year-old with LDL 130, ApoB 95, no diabetes, modest family history. ASCVD risk calculator says 10-year risk is 8%. Statin or not? Most current guidelines leave this judgment call to the clinician. Adding Lp-PLA2 (and ideally a coronary calcium scan) sharpens the decision considerably. Elevated Lp-PLA2 + non-zero coronary calcium = strong argument for statin. Normal Lp-PLA2 + zero calcium = strong argument for continued surveillance without statin.

For longevity-focused users running peptide protocols, Lp-PLA2 is less actionable on the protocol-tracking side and more actionable on the baseline-risk-stratification side. Pull it once during your initial advanced lipid panel along with ApoB, Lp(a), and hs-CRP. Repeat in 2-3 years or sooner if your ApoB or hs-CRP shifts meaningfully. The marker is too stable and too expensive to track quarterly.

Coronary calcium scoring as the complement

Lp-PLA2 measures vascular inflammation. Coronary calcium scoring (CAC, also called Agatston score) measures plaque calcification already present in the coronary arteries. The two are complementary: Lp-PLA2 catches early inflammation that hasn't calcified yet; CAC catches established plaque that may have started inflammation years ago.

In adults over 40 with any cardiovascular risk factor, the combination provides a more complete picture than either alone. A CAC score of 0 with elevated Lp-PLA2 suggests inflammation without established plaque - the window for aggressive lifestyle + lipid intervention before damage compounds. A CAC score of 100+ with normal Lp-PLA2 suggests established plaque but currently quiet inflammation - the window for plaque stabilization through statin therapy. A CAC of 100+ with elevated Lp-PLA2 = active plaque progression, often warranting more aggressive intervention.

The CAC scan itself is ~$100-200 at most imaging centers, takes 10 minutes, no IV contrast required. Combined with the $80 PLAC Test, the entire advanced vascular workup costs under $300 and provides genuinely actionable risk stratification.

*Educational reference only. This page is for educational purposes and is not medical advice. Cardiovascular risk stratification, including the appropriate use of advanced markers like Lp-PLA2, should be done with a clinician who knows your full history.*

Related Reading

• Apob Cardiovascular Risk Peptides →

Upload any lab PDF and MyProtocolStack maps your values to Lp-PLA2 and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.